#164: In diabetics, lifestyle management fails to reduce hard CV outcomes: Look AHEAD halted; rivaroxaban okayed for PE in Europe; PFO closure trials take spotlight at TCT 2012; small increased risk of CV events with diclofenac; FDA expands Sapien TAVI in

In diabetics, lifestyle management fails to reduce hard CV outcomes: Look AHEAD halted; rivaroxaban okayed for PE in Europe; PFO closure trials take spotlight at TCT 2012; small increased risk of CV events with diclofenac; FDA expands Sapien TAVI in

http://feedproxy.google.com/~r/radiotheheartorg/~3/dby6-Q0TIQ0/164-in-diabetics-...

Source: Radio TheHeart.org - October 26, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts